
Pyelonephritis- Pipeline Insight, 2024
Description
Pyelonephritis- Pipeline Insight, 2024
DelveInsight’s, “Pyelonephritis- Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Pyelonephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pyelonephritis: Overview
Pyelonephritis is a type of urinary tract infection where one or both kidneys become infected. They can be infected by bacteria or a virus. It can cause people to feel very sick and it requires treatment. There are approximately 250,000 cases of acute pyelonephritis each year, resulting in more than 100,000 hospitalizations. The most common etiologic cause is infection with Escherichia coli. The combination of the leukocyte esterase test and the nitrite test (with either test proving positive) has a sensitivity of 75 to 84 percent and a specificity of 82 to 98 percent for urinary tract infection. In Seattle, Washington, the annual risk of pyelonephritis is approximately 12–13/10 000 for women and 3–4/10 000 for men. Pyelonephritis can be stratified as ‘complicated’ or ‘uncomplicated’, depending on the presence of underlying urologic or medical conditions that predispose to kidney infection or that aggravate the severity or intransigence of such infections once they occur. Pyelonephritis is a potentially devastating complication of transplantation. Pyelonephritis can present as acute renal failure and cause graft loss. According to one series, pyelonephritis arises most often 1 year or more after transplantation (80% of episodes), and E. coli was the most common organism (80%).Acute pyelonephritis is a not an uncommon finding on renal biopsy, despite the expectation that the process is patchy. Renal biopsies are not the usual method of diagnosis, however, if neutrophils are abundant, especially if they form destructive abscesses and casts in tubules, the diagnosis should be at the top of the list. Other variants are emphysematous pyelonephritis, due to gas-producing organisms, xanthogranulomatous pyelonephritis and malakoplakia. Pyelonephritis is defined as infection and inflammation of the kidney and renal pelvis. Its diagnosis is clinical, and symptoms include back or flank pain with costovertebral angle tenderness on examination, fever (temperature higher than 38 °C), bacteriuria, and possibly nausea and vomiting. Dysuria is a less common presenting symptom for pyelonephritis. All patients with suspected pyelonephritis require a urinalysis and culture with sensitivity tests. Pyuria is almost universal in pyelonephritis, and white cell casts on urinalysis indicate upper urinary tract involvement. Infected patients can have an elevated white blood cell count, erythrocyte sedimentation rate, and C‐reactive protein. Imaging is not usually required to make the diagnosis of pyelonephritis. There are surprisingly few prospective randomized trials of the treatment of pyelonephritis. For patients who require hospitalization, parenteral therapy with an aminoglycoside, a third-generation cephalosporin, or a fluoroquinolone is recommended. The first decision in the management of patients with APN is whether or not the patient requires hospitalization. Although prospective randomized trials are lacking, several retrospective studies as well as several prospective nonrandomized trials suggest that outpatient management is safe for many patients. Hospitalization should be considered for patients who cannot tolerate oral intake or who have severe pain or signs of severe sepsis.
""Pyelonephritis- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pyelonephritis pipeline landscape is provided which includes the disease overview and Pyelonephritis treatment guidelines. The assessment part of the report embraces, in depth Pyelonephritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pyelonephritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Pyelonephritis R&D. The therapies under development are focused on novel approaches to treat/improve Pyelonephritis.
This segment of the Pyelonephritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pyelonephritis Emerging Drugs
- WCK-5222: Wockhardt
- XNW 4107: Sinovent
- ETX2514SUL: Entasis Therapeutics
Further product details are provided in the report……..
Pyelonephritis: Therapeutic Assessment
This segment of the report provides insights about the different Pyelonephritis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pyelonephritis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Pyelonephritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pyelonephritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pyelonephritis drugs.
Pyelonephritis Report Insights
- Pyelonephritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pyelonephritis drugs?
- How many Pyelonephritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pyelonephritis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pyelonephritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pyelonephritis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Wockhardt
- Sinovent
- Entasis Therapeutics
- Melinta Therapeutics
- WCK-5222
- XNW 4107
- ETX2514SUL
- ORBACTIV
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Pyelonephritis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Pyelonephritis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- WCK-5222: Wockhardt
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ETX2514SUL: Entasis Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Pyelonephritis Key Companies
- Pyelonephritis Key Products
- Pyelonephritis- Unmet Needs
- Pyelonephritis- Market Drivers and Barriers
- Pyelonephritis- Future Perspectives and Conclusion
- Pyelonephritis Analyst Views
- Pyelonephritis Key Companies
- Appendix
- *The Table of Contents is not exhaustive; will be provided in the final report
- List of Tables
- Table 1 Total Products for Pyelonephritis
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.